Assist. Prof., Director of Research @CincyUrology | @EAUGuidelines assoc | @EAUYAUrology #PCa | @OltreMedical @OltreDNA Passionate about #oncology #statistics
Cincinnati, OH
Joined December 2015
- Tweets586
- Following500
- Followers1.2K
- Likes1.9K
Pinned Tweet
I'm extremely happy to have received the @Uroweb Hans Marberger Award at #EAU22
Also great to see friends f2f again
#MedTwitter #UroSoMe – at Amsterdam, The Netherlands
#BCG_unresponsive #bladdercancer Are we comparing treatments or comparing trial designs?
Check out our new @BJUInt paper where we analyzed how differences in protocol design can substantially affect reported efficacy in BCG-unresponsive CIS trials
Trial design matters.
In BCG-U CIS, published CR rates are often compared across studies.
Our simulation analysis suggests that protocol differences may substantially influence reported efficacy.
Standardizing biopsy schedules and retreatment definitions will be critical for meaningful cross-trial comparisons, informed clinical decision-making and major guidelines implementation.
@IBCG_BladderCA @EauGuidelines @AmerUrological @FDA
Agreed.
Video from 180g RARP: tried to restore the funnel by extroflecting the anterior BN and "locking" the suture beyond the BN - similar to @AshTewariMD
Then reinforce posteriorly with a modified Pagano stitch @fabriziodalmoro
Yet, unfortunately reconstruction ≠preservation
6/8 Conceptually, preservation ≠ reconstruction. Our later @EUplatinum review framed bladder-neck preservation as preserving the preprostatic “internal” sphincter. Reconstruction can restore support; preservation aims to avoid disrupting functional anatomy in the first place.
Completely agree. When feasible, I try to "carve" out the urethra, and do so anteriorly even when I can't preserve the BN in toto due to a median lobe for example.
In case of good preservation the bladder remains "continent" for the procedure
@IntuitiveSurg #DaVinci5
We reported on DASH, or lower detrusor apron sparing, or PATENTs, with iNEOB with @GPloussard @UroTouzani while at @UROSUD1
Small case load, patient selection plays a role, but very encouraging outcomes.
#Surginmotion video (@IntuitiveSurg Si) in @EurUrolFocus
Personally, I am a big fan of antegrade NS without opening the endopelvic fascia and maximal bladder neck preservation since my time with @AshTewariMD
Also, good data on Unilat Hood @GPloussard @AmbroiseSalin to be released soon
nitter.cf/AlbertoMartini_/status…
@jimhumd @JackAndrewsMD
Hood #robotic #prostatectomy with maximal bladder neck preservation ↙️
Although I mostly trained with a non-BN approach, I switched to BN preservation whenever feasible and do not perform posterior reconstruction/Rocco stitch
Exciting progress in BCG-unresponsive NMIBC. Our @TheLancetOncol commentary explores the promise of cretostimogene, balancing impressive durability and safety data with the key questions that still need answers.
pubmed.ncbi.nlm.nih.gov/4250…
As the field rapidly advances, it is critical to focus not only on response rates but also on the durability and timing of responses, the impact of re-induction, outcomes for non-responders, and costs.
More research on the topic on its way! Also presented at #EAU26
sciencedirect.com/science/ar…
@DRobesti @GFallara_MD @UroDocAsh @GPloussard
Alberto Martini retweeted
New paper just out in @EurUrolOncol - outcomes of patients with intermediate-risk NMIBC when treated with contemporary protocols?
We analyzed 578 patients across 4 RCTs. IR NMIBC defined as per @IBCG_BladderCA and 2019 EAU Guidelines - only LG tumors.
Real-world relevant data. Here is what we found. 🧵
Ohttps://euoncology.europeanurology.com/article/S2588-9311%2826%2900127-6/fulltext
Alberto Martini retweeted
IR NMIBC (Recurrent LG) of UK RCT- HIVEC-II, BOXIT, PHOTO, CALIBER suggest that despite 6 weekly induction chemotherapy nearly 50% develop recurrence at 5 yrs
⭐️Important bench mark to beat for upcoming RCT using surveillance as control
shorturl.at/z8Jja
New paper just out in @EurUrolOncol - outcomes of patients with intermediate-risk NMIBC when treated with contemporary protocols?
We analyzed 578 patients across 4 RCTs. IR NMIBC defined as per @IBCG_BladderCA and 2019 EAU Guidelines - only LG tumors.
Real-world relevant data. Here is what we found. 🧵
Ohttps://euoncology.europeanurology.com/article/S2588-9311%2826%2900127-6/fulltext
Alberto Martini retweeted
“Advances in Management of Urothelial Carcinoma” at #OUS2026
Moderated by Dr. Firas Petros
Speakers:
@AlbertoMartini_ @CincyUrology
@LauraBukavinaMD @CleClinicUro
Dr. Ahmad Shabsigh @OSU_Urology
#OhioUrology
#BladderCancer management changes rapidly.
Here is a concise #evidencebased overview clinicians can use:
bestpractice.bmj.com/topics/…
Thank you @BMJBestPractice @bmj_company for the invitation. Special thanks to the reviewers and prior contributors.
I had a great time at @smumexico in @GuadalajaraGob
I really enjoyed the debates, the program, and the whole meeting!
Thank you again, @RomanCarvajal & @AlexHermen, and congrats on an outstanding conference!
Seguimos fortaleciendo conocimientos en Plenarias durante el Módulo Cáncer de Próstata, expertos compartieron evidencia, técnicas actualizadas y perspectivas clave para elevar la práctica diaria. 👥🩺 ¡Agradecemos a cada uno por su experiencia, claridad y compromiso con nuestra membresía!
#SMU25 #UrologíaEnMovimiento
Alberto Martini retweeted
🚨🗣️ Simposio @ecancer @ecancer_espanol en cáncer urotelial
Imperdible foro durante #SMU25, coordinado por la gran @ReginaBarCar 🔝👏🏻 y un faculty 🤩🔥 @carme_mir1 @nataliagandur @MRadonc @LAUrology_NL @GustavoVillold4 @AlbertoMartini_ @castialon @urologohector 🇪🇸🇦🇷🇮🇹🇳🇱🇺🇸🇲🇽
